Introduction
============

Kidney renal clear cell carcinoma (KIRC) is the eighth most common type of cancer, which accounts for the majority of malignant kidney tumors ([@b1-mmr-15-04-1661]). KIRC is known to be associated with radiotherapy and chemotherapy resistance ([@b2-mmr-15-04-1661]), and the 2-year survival rate of patients with metastatic KIRC is \<20% ([@b3-mmr-15-04-1661],[@b4-mmr-15-04-1661]). Early diagnosis and surgical resection may result in a good prognosis; therefore, further investigations regarding the genomic alterations and underlying molecular mechanisms of KIRC are essential for improvements in early diagnosis and treatment.

Certain advances have been made in unveiling the complicated molecular mechanisms underlying KIRC, since numerous relevant pathways have been implicated in its pathogenesis. Components of the mammalian target of rapamycin pathway have been reported to be significantly associated with the pathological features and survival of KIRC ([@b5-mmr-15-04-1661]). Frequent mutations in genes encoding ubiquitin-mediated proteolysis pathway components have also been observed in KIRC ([@b6-mmr-15-04-1661]). The Sonic hedgehog signaling pathway ([@b7-mmr-15-04-1661]) and MYC pathway ([@b8-mmr-15-04-1661]) are also activated in KIRC and serve a role in tumor growth. Furthermore, numerous biomarkers have been identified, including cluster of differentiation 70 ([@b8-mmr-15-04-1661]), succinate dehydrogenase B ([@b8-mmr-15-04-1661]) and transforming growth factor beta 1 ([@b9-mmr-15-04-1661]). Nevertheless, further studies are required to identify novel prognostic genes and provide potential therapeutic targets.

Previous studies have focused on the identification of differentially expressed genes, which may serve roles in the pathogenesis of KIRC ([@b10-mmr-15-04-1661],[@b11-mmr-15-04-1661]). The present study performed a gene co-expression network analysis and a survival analysis on RNA-seq data in order to screen out prognostic genes in KIRC. These findings may help improve understanding regarding the pathogenesis of KIRC, and also provide potential markers for prognosis and treatment.

Materials and methods
=====================

### Gene expression data

RNA-seq (Illumina RNASeqV2, Level 3; Illumina, San Diego, CA, USA) rsem.gene.results data of KIRC were downloaded from The Cancer Genome Atlas (TCGA; <https://cancergenome.nih.gov/>) on September 25, 2015, including 533 KIRC samples. Clinical information, including status, follow-up time and time of death, was also collected.

### Screening of feature genes

Raw data were normalized and filtered using the TCGAbiolinks package in R (version 3.2.2, <http://www.r-project.org/>). Genes with an average expression level \<0.25 in all samples were excluded from the subsequent analyses. Feature genes with a coefficient of variation (CV) \>0.5 in all samples were selected using the genefilter package in R.

### Construction of a gene co-expression network

The KIRC samples were divided into two sets: The training set (n=319 samples) and the validation set (n=214 samples), with a ratio of 3:2 using the caTools package in R.

Gene co-expression networks were constructed using the weighted gene co-expression network analysis (*WGCNA*) ([@b12-mmr-15-04-1661]) package in *R*. Adjacency coefficient (*aij*) was calculated as follows:
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Where *xi* and *xj* are vectors of expression value for genes *i* and *j*; *cor* represents Pearson\'s correlation coefficient of the two vectors; and *aij* is adjacency coefficient, which is acquired via exponential transform of *Sij*.

The WGCNA method takes topological properties into consideration in order to identify modules from a gene co-expression network. Therefore, this method not only considers the relationship between two connected nodes, but also takes associated genes into account. Weighting coefficient (*Wij*) is calculated from *aij* as follows:
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Where u represents common genes linked gene I and gene j together; aiu, the connection coefficient of gene i and gene u; and auj, the connection coefficient of gene u and gene j. *Wij* considers overlapping between neighbor genes of genes *i* and *j*. Modules were identified via hierarchical clustering of weighting coefficient matrix *W*.

### Survival analysis

A univariate Cox regression analysis was performed using the survive package in R.

### Functional enrichment analysis

Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using DAVID (Database for Annotation, Visualization and Integration Discovery; <http://david.abcc.ncifcrf.gov/>) ([@b13-mmr-15-04-1661]).

### Validation of the hub genes

A KIRC gene expression dataset (accession no. E-GEOD-22541) was downloaded from ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) to validate the reliability of the 11 hub genes. Cases were divided into two groups (high and low) based upon the expression levels of certain hub genes, using the gene average expression level in all samples as the cut-off. The samples in which the gene expression level were higher than average expreesion level were defined as high exp; the other samples were defined as low exp, correspondingly. Survival analysis was performed using the Kaplan-Meier method.

Results
=======

### Feature genes

A total of 533 KIRC samples were collected from TCGA. After pretreatment, 13,742 genes were selected according to the threshold (average expression level \>0.25 in all samples). Finally, 6,758 feature genes with a CV \>0.5 were acquired for further analysis.

### Gene co-expression network

The training set included 319 samples and the validation set contained 214 samples. The training set was used to construct a gene co-expression network, whereas the validation set was used to examine the stability and accuracy of the network. The soft threshold was set as 5 to construct the network ([Fig. 1](#f1-mmr-15-04-1661){ref-type="fig"}).

When the soft threshold was set as 5, both training set and validation set networks obeyed power-law distribution, exhibiting scale-free characteristics ([Fig. 2](#f2-mmr-15-04-1661){ref-type="fig"}). The correlation coefficient between the two networks was 0.75, when the soft threshold was 5.

### Survival-related modules

A total of 12 modules were revealed using the cuttreeStaticColor function from WGCNA package (cutHeight=0.93; minSize=50) ([Fig. 3](#f3-mmr-15-04-1661){ref-type="fig"}). A Cox regression analysis was performed for each gene in both datasets and a P-value was obtained. Hub genes may serve critical roles in disease; therefore, degree (k) was also calculated for each gene. The correlation between k and -log10(p) was subsequently determined. Survival-associated genes were significantly over-represented in the green module ([Fig. 4](#f4-mmr-15-04-1661){ref-type="fig"}).

### Biological functions of the green module

Significantly over-represented GO biological process terms ([Table I](#tI-mmr-15-04-1661){ref-type="table"}) and KEGG pathways ([Table II](#tII-mmr-15-04-1661){ref-type="table"}) were identified for genes from the green module. The cell cycle and p53 signaling pathway were revealed to be closely associated with KIRC.

### Hub genes in the green module

A total of 202 genes were included in the green module. Genes with P\<0.01 in the Cox regression analysis of the training and validation sets were selected. The intramodular degree (kWithin) was then calculated for each gene. The top 20 genes in the training and validation sets were subsequently obtained. The overlapping genes were regarded as hub genes. A total of 11 hub genes were identified ([Table III](#tIII-mmr-15-04-1661){ref-type="table"}): Cyclin A2 (CCNA2), cyclin B2 (CCNB2), cell division cycle 20 (CDC20), cell division cycle associated 8 (CDCA8), G2 and S-phase expressed 1 (GTSE1), kinesin family member 23 (KIF23), kinesin family member 2C (KIF2C), kinesin family member 4A (KIF4A), maternal embryonic leucine zipper kinase (MELK), topoisomerase II alpha (TOP2A) and TPX2 microtubule-associated (TPX2).

### Validation of the hub genes

With the exception of CCNB2, the other 10 hub genes exhibited good prognostic effects in the validation dataset E-GEOD 22541. The Kaplan-Meier survival curve of CCNA2 is presented in [Fig. 5](#f5-mmr-15-04-1661){ref-type="fig"}.

Discussion
==========

In the present study, a total of 533 KIRC samples were collected from TCGA and 6,758 feature genes were revealed, based upon which gene co-expression networks were constructed. A total of 12 modules were identified; however, only one module (green) was significantly associated with survival time. The green module included 202 genes, which were implicated in the cell cycle and p53 signaling pathway. Finally, a total of 11 hub genes were revealed by network analysis combined with survival analysis; 10 of which were validated using another gene expression dataset.

The majority of the validated hub genes were involved in the cell cycle, including CCNA2, CDC20 and CDCA8. CDC20 acts as a regulatory protein at numerous points in the cell cycle. It is negatively regulated by p53 and may be considered a good potential therapeutic target ([@b14-mmr-15-04-1661]). Increased TOP2A expression is associated with more aggressive pathological features and an increased risk of cancer-specific mortality among patients undergoing surgery for localized KIRC ([@b15-mmr-15-04-1661]). Chen *et al* indicated that TOP2A is a prognostic marker in advanced renal cell carcinoma ([@b16-mmr-15-04-1661]). Furthermore, overexpression of TOP2A has been reported in other types of cancer ([@b17-mmr-15-04-1661],[@b18-mmr-15-04-1661]) and is considered a therapeutic target ([@b19-mmr-15-04-1661]). The results of the present study indicated that it may also be a therapeutic target in KIRC. GTSE1 accumulates in the nucleus and binds to p53, resulting in its translocation out of the nucleus and suppression of its apoptosis-inducing ability. In addition, GTSE1 suppresses apoptotic signaling and confers cisplatin resistance in gastric cancer cells ([@b20-mmr-15-04-1661]). Overexpression of GTSE1 has previously been observed in KIRC ([@b21-mmr-15-04-1661]) and may therefore exert a similar function in KIRC.

Several prognostic genes have been implicated in various types of cancer; however, their roles in KIRC require further research. Kinesins are a family of molecular motor proteins that travel along microtubule tracks in order to fulfill their numerous roles in intracellular transport and cell division ([@b22-mmr-15-04-1661]). Several kinesins that are involved in mitosis have emerged as potential targets for cancer drug development ([@b23-mmr-15-04-1661]). Three kinesins (KIF23, KIF2C and KIF4A) were identified as prognostic genes in KIRC in the present study. Previous studies have indicated their roles in lung cancer ([@b24-mmr-15-04-1661]), colorectal cancer ([@b25-mmr-15-04-1661]) and oral cancer ([@b26-mmr-15-04-1661]). MELK, which is a highly conserved serine/threonine kinase, is a regulator in cell cycle control and cancer ([@b27-mmr-15-04-1661],[@b28-mmr-15-04-1661]). Dysregulated expression of MELK is associated with a poor prognosis in breast cancer ([@b29-mmr-15-04-1661]). In addition, a MELK inhibitor has been reported to have potential as a novel molecular targeted therapy, which targets human cancer stem cells ([@b30-mmr-15-04-1661]). TPX2 is associated with various types of cancer, including esophageal squamous cell carcinoma ([@b31-mmr-15-04-1661]), bladder carcinoma ([@b32-mmr-15-04-1661]) and cervical carcinoma ([@b33-mmr-15-04-1661]). In addition, it contributes to the growth and metastasis of hepatocellular carcinoma ([@b34-mmr-15-04-1661]). Further studies regarding these genes may provide novel insights into the pathogenesis of KIRC and provide potential prognostic markers.

In conclusion, the present study identified 11 critical genes associated with KIRC. The prognostic value of 10 genes was validated using another gene expression dataset, which provides important evidence regarding the pathogenesis of KIRC. Further studies are required to better define their roles in KIRC.
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![Distribution of genes in terms of degree (soft threshold, 5). (A) Training set; (B) Validation set; X-axis indicates degree *k*; Y-axis indicates percentage of genes with degree *k*. (C) Correlation between the training dataset and validation dataset co-expression networks. The x-axis indicates degree k in the training dataset; y-axis indicates degree k in the validation dataset.](MMR-15-04-1661-g05){#f2-mmr-15-04-1661}

![Results of a cluster analysis, and 12 modules identified from the gene expression networks. (A) Training set; (B) validation set. Gray represents no module.](MMR-15-04-1661-g06){#f3-mmr-15-04-1661}

![Enrichment of survival-associated genes in each module. (A) Training set; (B) validation set. X-axis indicates modules; Y-axis indicates significance of enrichment.](MMR-15-04-1661-g07){#f4-mmr-15-04-1661}

![Kaplan-Meier survival curves of CCNA2. Based on gene expression data from (A) TCGA and the (B) E-GEOD-22541 dataset. CCNA2, cyclin A2; TCGA, the Cancer Genome Atlas.](MMR-15-04-1661-g08){#f5-mmr-15-04-1661}

###### 

Top 10 GO biological process terms of genes from the green module.

  No.          Biological process              Count   P-value
  ------------ ------------------------------- ------- ----------
  GO:0007049   Cell cycle                      98      1.85E-74
  GO:0022403   Cell cycle phase                79      3.66E-72
  GO:0000279   M phase                         73      4.21E-71
  GO:0022402   Cell cycle process              83      1.43E-66
  GO:0000278   Mitotic cell cycle              68      7.52E-60
  GO:0000280   Nuclear division                56      8.53E-57
  GO:0007067   Mitotic nuclear division        56      8.53E-57
  GO:0000087   M phase of mitotic cell cycle   56      2.56E-56
  GO:0048285   Organelle fission               56      9.80E-56
  GO:0051301   Cell division                   54      1.95E-46

GO, gene ontology.

###### 

Significantly over-represented Kyoto Encyclopedia of Genes and Genomes pathways of genes from the green module.

  No.        Pathway                                   Count   P-value
  ---------- ----------------------------------------- ------- ----------
  hsa04110   Cell cycle                                25      2.63E-23
  hsa04114   Oocyte meiosis                            13      7.35E-09
  hsa04914   Progesterone-mediated oocyte maturation   11      8.09E-08
  hsa04115   p53 signaling pathway                       7     1.86E-04
  hsa03440   Homologous recombination                    5     3.73E-04

###### 

Summary of the 11 hub genes.

          P-value    *k* Total   *k* Within                     
  ------- ---------- ----------- ------------ -------- -------- --------
  CCNA2   2.29E-06   8.15E-11    85.594       57.123   68.745   48.839
  CCNB2   9.08E-07   1.89E-08    94.399       68.515   72.728   55.378
  CDC20   6.17E-08   1.27E-08    93.507       60.032   74.198   50.181
  CDCA8   2.76E-05   5.21E-08    89.649       64.707   73.107   52.065
  GTSE1   1.88E-06   1.30E-08    93.828       63.922   73.780   53.611
  KIF23   3.21E-08   1.07E-08    91.183       60.441   69.097   48.626
  KIF2C   3.00E-07   8.09E-08    88.153       64.374   70.517   54.608
  KIF4A   1.14E-04   4.07E-08    92.184       63.336   69.749   51.397
  MELK    9.74E-07   2.37E-07    85.264       60.536   69.125   52.317
  TOP2A   3.88E-08   1.72E-08    88.265       61.531   72.680   53.977
  TPX2    7.24E-07   1.40E-08    88.309       68.001   71.906   57.164

T set, training set; V set, validation set; CCNA2, cyclin A2; CCNB2, cyclin B2; CDC20, cell division cycle 20; CDCA8, cell division cycle associated 8; GTSE1, G2 and S-phase expressed 1; KIF23, kinesin family member 23; KIF2C, kinesin family member 2C; KIF4A, kinesin family member 4A; MELK, maternal embryonic leucine zipper kinase; TOP2A, topoisomerase II alpha; TPX2, TPX2 microtubule-associated.
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